In the wake of the FDA's second rejection of non-small-cell lung cancer candidate Xcytrin, Pharmacyclics Inc. is slashing its work force by 40 percent and refocusing resources on its earlier-stage pipeline in cancer and immune-mediated diseases. (BioWorld Today)